Autoimmunity and Post-Viral Immune Dysregulation
1 Son et al. 2023 — Anti-Nuclear Autoantibodies in COVID-19 Survivors Predict Long COVID
Full Citation:: Son K, Jamil R, Chowdhury A, Mukherjee M, et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. European Respiratory Journal. 2023;61(3):2200970. (Son et al. 2023) DOI:: 10.1183/13993003.00970-2022 PMID:: 36137590 Study Design:: Prospective longitudinal cohort Sample Size:: \(n=106\) convalescent COVID-19 patients followed at 3, 6, and 12 months Key Findings::
- ANA positivity at 3 months post-infection predicted persistent fatigue, dyspnoea, and cough at 12 months
- Specific autoantibodies (U1-snRNP and anti-SS-B/La) correlated independently with fatigue severity
- Elevated TNF-$\alpha$ independently predicted both ANA persistence and symptom burden at 12 months
- Autoantibody profile resembled early mixed connective tissue diseaseRelevance:: Establishes anti-nuclear autoantibodies as predictive biomarkers for Long COVID, particularly for fatigue. Raises the question of whether post-viral ME/CFS shares this autoimmune substrate, and whether TNF-\(\alpha\)-driven ANA induction is a targetable mechanism. Certainty Assessment::
- *Quality:* Medium-High (European Respiratory Journal, prospective longitudinal)
- *Sample:* $n=106$
- *Replication:* Partially replicated (consistent with broader post-COVID autoantibody literature)
- *Certainty:* 0.652 Guedes de S'a et al. 2024 — Causal Link Between Autoantibodies and Neurological Long COVID
Full Citation:: Guedes de S'a KS, Silva J, Bayarri-Olmos R, et al. A causal link between autoantibodies and neurological symptoms in long COVID. medRxiv [preprint]. 2024. (Guedes de Sá et al. 2024) DOI:: 10.1101/2024.06.18.24309100 PMID:: 38947091 Note:: Preprint — peer-reviewed publication status unverified at time of writing. Study Design:: Proteome-wide autoantibody array (\(>\) 21000 human proteins) \(+\) passive IgG transfer to mice Key Findings::
- Diverse autoantibodies against nervous system targets identified in Long COVID patients with neurological symptoms
- Passive transfer of purified patient IgG to mice reproduced pain hypersensitivity, balance loss, and disorientation
- Autoantibodies targeted pons, meninges, spinal cord, and sciatic nerve
- Meningeal antibody reactivity correlated with headache; sciatic nerve reactivity correlated with disorientationRelevance:: Passive transfer experiment establishes causal sufficiency of autoantibodies for neurological symptoms — the same gold-standard design used to confirm NMO-IgG and NMDAR encephalitis. Pontine autoantibody targeting is directly relevant to ME/CFS brainstem and autonomic dysfunction hypotheses. Identifies autoantibody removal (plasmapheresis, IVIG, rituximab) as the mechanistically appropriate intervention. Certainty Assessment::
- *Quality:* High mechanistic design; preprint status
- *Replication:* Not independently replicated
- *Certainty:* 0.60
- *Limitation:* Preprint; requires peer review and independent replication3 Goldstein et al. 2024 — Persistent Autonomic Abnormalities in Neuro-PASC
Full Citation:: Goldstein DS, Mina Y, Walitt B, Sullivan P, Enose-Akahata Y, Jacobson S, Nguyen D, Sidenko S. Persistent autonomic and immunologic abnormalities in neurologic post-acute sequelae of SARS-CoV2 infection. Neurology. 2024;103(6):e209742. (Goldstein et al. 2024) DOI:: 10.1212/WNL.0000000000209742 PMID:: 39173103 Study Design:: Longitudinal observational follow-up (≥1 year) Key Findings::
- Autonomic and immunologic abnormalities persist at least 1 year after initial Neuro-PASC evaluation at NIH Clinical Center
- Included CSF catecholamines, autonomic function testing, immune markers
- Same NIH research group as Walitt 2024 and Aregawi 2026 — methodological consistencyConclusion:: Autonomic dysfunction in Neuro-PASC is persistent over ≥1 year; central noradrenergic abnormalities do not resolve spontaneously. Limitations:: Observational; no control group at follow-up; same NIH center as related studies. Certainty Assessment::
- *Quality:* High (Neurology; longitudinal design)
- *Sample:* Medium
- *Replication:* Not independently replicated
- *Score:* 0.704 Hendrix et al. 2025 — Adrenergic Dysfunction in ME/CFS and Fibromyalgia: Meta-Analysis
Full Citation:: Hendrix J, Fanning L, Wyns A, Ahmed I, Patil MS, Richter E, et al. Adrenergic dysfunction in patients with myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia: a systematic review and meta-analysis. European Journal of Clinical Investigation. 2025;55(1):e14318. (Hendrix et al. 2025) DOI:: 10.1111/eci.14318 PMID:: 39319943 Study Design:: Systematic review and meta-analysis Key Findings::
- Adrenergic dysfunction confirmed in ME/CFS and FM across multiple studies
- Elevated catecholamines and altered adrenergic receptor function
- Heterogeneous outcomes across studies; no single biomarker identifiedConclusion:: Adrenergic dysfunction is a confirmed feature of ME/CFS, supporting sympathetic nervous system involvement. However, measurement heterogeneity limits clinical translation. Limitations:: Heterogeneous study methodologies; limited number of studies with comparable outcomes. Certainty Assessment::
- *Quality:* High (systematic review methodology)
- *Sample:* Large combined sample
- *Replication:* N/A (meta-analysis)
- *Score:* 0.655 Sulheim et al. 2014 — Clonidine in Adolescent CFS: Sympathetic Activity Hypothesis
Full Citation:: Sulheim D, Fagermoen E, Winger A, Andersen AM, Godang K, Müller F, Rowe PC, Saul JP. Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial. JAMA Pediatrics. 2014;168(4):351–360. (Sulheim et al. 2014) DOI:: 10.1001/jamapediatrics.2013.4647 PMID:: 24493300 Study Design:: Cross-sectional + double-blind RCT (clonidine vs placebo) Sample Size:: n=120 adolescents with CFS Key Findings::
- Enhanced sympathetic activity hypothesized; clonidine (α2 agonist) tested as sympatholytic
- Clonidine did not improve symptoms despite reducing sympathetic tone
- Suggests sympathetic activation is compensatory, not primary pathological driver
- Important negative result for noradrenergic intervention in ME/CFSConclusion:: Clonidine is ineffective in adolescent CFS. Sympathetic activation may be compensatory rather than causal. Null finding constrains the noradrenergic hypothesis. Limitations:: Single-center Norwegian cohort; adolescent only; clonidine side effects may have unblinded participants. Certainty Assessment::
- *Quality:* High (JAMA Pediatrics; RCT design)
- *Sample:* Medium (n=120)
- *Replication:* Single study
- *Score:* 0.656 Kristiansen et al. 2019 — Post-EBV Catecholamines in Adolescent Chronic Fatigue
Full Citation:: Kristiansen MS, Stabursvik J, O’Leary E, Pedersen M, Asprusten T, Leegaard T, Osnes T, Tjade T. Clinical symptoms and markers of disease mechanisms in adolescent chronic fatigue following Epstein-Barr virus infection: an exploratory cross-sectional study. Brain, Behavior, and Immunity. 2019;80:551–563. (Kristiansen et al. 2019) DOI:: 10.1016/j.bbi.2019.04.040 PMID:: 31039432 Study Design:: Exploratory cross-sectional study (post-EBV) Sample Size:: n=200 adolescents assessed 6 months after acute EBV Key Findings::
- Catecholamine and autonomic markers assessed in fatigued vs recovered subgroups after EBV
- Post-viral fatigue model directly relevant to PI-ME/CFS paradigm
- Supports post-infectious noradrenergic dysregulation hypothesisConclusion:: Post-EBV chronic fatigue is associated with catecholaminergic and autonomic dysregulation, consistent with Aregawi 2026 findings in PI-ME/CFS. Limitations:: Exploratory design; cross-sectional at single timepoint; adolescent only. Certainty Assessment::
- *Quality:* High (Brain, Behavior, and Immunity)
- *Sample:* Large (n=200)
- *Replication:* Single study
- *Score:* 0.607 Winkler et al. 2016 — Catecholamine Responses in CFS (Peripheral NE)
Full Citation:: Winkler B, et al. Catecholamine responses in chronic fatigue syndrome. Neurological Sciences. 2016;37(12):1933–1939. (Winkler et al. 2016) DOI:: 10.1007/s10072-016-2699-0 PMID:: 27727448 Study Design:: Cross-sectional Key Findings::
- Elevated plasma norepinephrine at rest in CFS patients vs controls
- Supports central-peripheral NE mismatch: low CNS NE (Aregawi 2026) with high peripheral NEConclusion:: Peripheral catecholamines are elevated in CFS, contrasting with central NE deficiency — consistent with compartment-specific noradrenergic dysregulation. Limitations:: Small sample; no CSF measurement; cross-sectional. Certainty Assessment::
- *Score:* 0.608 Wyller et al. 2016 — Altered Neuroendocrine Control in Adolescent CFS
Full Citation:: Wyller VBB, Vitelli V, Sulheim D, Fagermoen E, Winger A, Godang K, Bollerslev J. Altered neuroendocrine control and association to clinical symptoms in adolescent chronic fatigue syndrome: a cross-sectional study. Journal of Translational Medicine. 2016;14(1):121. (Wyller et al. 2016) DOI:: 10.1186/s12967-016-0873-1 PMID:: 27149955 Study Design:: Cross-sectional case-control Sample Size:: n=120 adolescent CFS Key Findings::
- HPA axis attenuation with SAM (sympathetic/adrenal medulla) system enhancement
- Enhanced sympathetic activity observed
- Network analyses linked neuroendocrine variables to clinical symptomsConclusion:: Neuroendocrine dysregulation in adolescent CFS involves both HPA suppression and SAM activation — consistent with central-peripheral NE mismatch pattern. Limitations:: Cross-sectional; adolescent only; single Norwegian center. Certainty Assessment::
- *Score:* 0.559 Young et al. 2025 — Solriamfetol (NDRI) RCT in ME/CFS
Full Citation:: Young JL, Bateman L, Helliwell S, Klimas NG, Ruhoy IS, Kilduff TS. Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment. Journal of Psychopharmacology. 2025;39(11):1268–1276. (Young et al. 2025) DOI:: 10.1177/02698811251368371 PMID:: 40958377 Study Design:: Phase 4 double-blind RCT (solriamfetol 75-150 mg vs placebo) Sample Size:: n=38 ME/CFS Key Findings::
- Solriamfetol (dual norepinephrine-dopamine reuptake inhibitor) improved fatigue severity at week 8 (p=0.039)
- Improved executive function (metacognition index p=0.004)
- PEM not assessed — cannot evaluate effect on PEM specificallyConclusion:: NDRI class shows preliminary efficacy for fatigue in ME/CFS. Supports NE reuptake inhibition as therapeutic strategy. PEM-specific effects need dedicated study. Limitations:: Small sample (n=38); moderate effect; PEM not assessed; short duration (8 weeks). Certainty Assessment::
- *Quality:* Medium-High (RCT design; small n)
- *Sample:* Small (n=38)
- *Replication:* Single trial
- *Score:* 0.5510 Mwesigwa et al. 2024 — Atomoxetine (NRI) for Neurogenic Orthostatic Hypotension
Full Citation:: Mwesigwa N, Millar Vernetti P, Kirabo A, Black B, Ding T, Martinez J, Palma JA, Biaggioni I. Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial. Clinical Autonomic Research. 2024;34(6):561–569. (Mwesigwa et al. 2024) DOI:: 10.1007/s10286-024-01051-2 PMID:: 39294522 Study Design:: Randomized, double-blind, placebo-controlled crossover trial Key Findings::
- Atomoxetine (selective norepinephrine reuptake inhibitor) improved standing blood pressure in nOH
- 4-week treatment period with crossover design
- Demonstrates NE reuptake inhibition can improve autonomic functionConclusion:: Atomoxetine is effective for nOH via NE reuptake blockade. Translational relevance: if central NE deficiency drives autonomic dysfunction in ME/CFS, atomoxetine may be mechanistically targeted. No ME/CFS-specific atomoxetine data exist. Limitations:: nOH population not ME/CFS; short duration; crossover design limitations. Certainty Assessment::
- *Score:* 0.5511 Natelson et al. 2015 — Milnacipran (SNRI) Ventricular Lactate in Fibromyalgia
Full Citation:: Natelson BH, Vu D, Mao X, Weiduschat N, Togo F, Lange G, Blate M, Kang G. Effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Pain. 2015;16(11):1211–1219. (Natelson et al. 2015) DOI:: 10.1016/j.jpain.2015.08.004 PMID:: 26335989 Study Design:: RCT (milnacipran vs placebo); MRS lactate endpoint Key Findings::
- Milnacipran (SNRI) did not lower ventricular lactate despite clinical improvement in some
- SNRIs clinically effective in FM but mechanism may not be via brain energy metabolism
- Relevant to NE-PEM-metabolism connectionConclusion:: SNRIs improve FM symptoms but mechanism uncertain. Does not support brain lactate reduction as NE-mediated mechanism. Limitations:: FM population not ME/CFS; modest sample; MRS technical limitations. Certainty Assessment::
- *Score:* 0.5512 Arnold et al. 2004 — Duloxetine in Fibromyalgia (Landmark SNRI RCT)
Full Citation:: Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism. 2004;50(9):2974–2984. (Arnold et al. 2004) PMID:: 15457467 Study Design:: Multi-center RCT (duloxetine vs placebo) Sample Size:: n=207 fibromyalgia patients Key Findings::
- Duloxetine (SNRI) improved pain and fatigue in fibromyalgia independent of depression
- Established SNRI efficacy in FM; NE reuptake mechanism central
- Foundation for NE reuptake as therapeutic target in related conditionsConclusion:: Dual serotonin-norepinephrine reuptake inhibition is effective for fibromyalgia pain and fatigue. SNRI efficacy supports NRI mechanistic rationale for ME/CFS fatigue. Limitations:: FM population not ME/CFS; fibromyalgia pain more prominent than in ME/CFS; older study (2004). Certainty Assessment::
- *Quality:* High (Arthritis and Rheumatism; multi-center RCT)
- *Sample:* Large (n=207)
- *Replication:* Well-replicated (multiple subsequent SNRI trials in FM)
- *Score:* 0.6513 Malik et al. 2025 — SNRIs for Fibromyalgia: Comprehensive Clinical Review
Full Citation:: Malik A, Brown Z, Ryder A, Balayan V, Jameson L, Vu P, Al-Jumah A, Hasoon J. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review. Psychopharmacology Bulletin. 2025;55(2):24–40. (Malik et al. 2025) DOI:: 10.64719/pb.4519 PMID:: 39935669 Study Design:: Comprehensive clinical review Key Findings::
- SNRIs (duloxetine, milnacipran) effective for fibromyalgia pain and fatigue
- NE reuptake mechanism central to clinical efficacy
- Review supports NRI mechanistic rationale for fatigue treatmentConclusion:: SNRIs are established treatments for FM with NE reuptake as key mechanism. Supports exploration of NE reuptake agents in ME/CFS. Limitations:: Review article; FM-focused; no ME/CFS-specific data. Certainty Assessment::
- *Score:* 0.50